MV Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

MV Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08K	Sell	32 -23	-42%	-$766	﹤0.01%	898
2026 Q1	$1.66K	Buy	55 +39	+244%	+$1.25K	﹤0.01%	776
2025 Q4	$500	Buy	+16	New	+$394	﹤0.01%	919
2017 Q2	–	Sell	-3,190	Closed	-$102K	–	369
2017 Q1	$102K	Buy	3,190 +16	+0.5%	+$546	0.03%	131
2016 Q4	$115K	Sell	3,174 -373	-11%	-$14.9K	0.04%	116
2016 Q3	$163K	Sell	3,547 -482	-12%	-$25.1K	0.06%	96
2016 Q2	$202K	Buy	+4,029	New	+$214K	0.07%	90
2015 Q1	–	Sell	-40	Closed	-$2K	–	512
2014 Q4	$2K	Buy	+40	New	+$2.23K	﹤0.01%	500

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

MV Capital Management's TEVA Position: Q2 2026 in Review

MV Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 42% in Q2 2026, selling an estimated $766 and leaving 32 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #898.

MV Capital Management first reported a position in TEVA in Q4 2014 and has held it in 8 quarters since. The position peaked at $202K in Q2 2016. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

MV Capital Management held 32 shares of Teva Pharmaceuticals worth $1.08K as of Q2 2026.
MV Capital Management sold 23 Teva Pharmaceuticals shares in Q2 2026, an estimated $766.
Teva Pharmaceuticals made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #898 holding.
MV Capital Management first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 8 quarters since.
MV Capital Management's Teva Pharmaceuticals position peaked at $202K in Q2 2016.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.